Other Events ·
Protara Therapeutics, Inc. held its Annual Meeting of Stockholders on June 12, 2026
PRTOProtara Therapeutics, Inc.
Protara Therapeutics, Inc. held its Annual Meeting of Stockholders on June 12, 2026. Shareholders elected Jesse Shefferman, Barry Flannelly, and Cynthia Smith as Class III directors. The meeting resulted in the ratification of Ernst and Young LLP as the independent registered public accounting firm for the 2026 fiscal year. Stockholders approved an amendment to the 2024 Equity Incentive Plan and an amendment to the Certificate of Incorporation to increase authorized common stock from 100,000,000 to 200,000,000 shares. Additionally, an amendment allowing officer exculpation was approved. Advisory votes regarding executive compensation and the frequency of say-on-pay votes were also conducted. Protara Therapeutics, Inc. is a biotechnology company.